A therapy-grade protocol for differentiation of pluripotent stem cells into mesenchymal stem cells using platelet lysate as supplement

Table 1 Comparative cell surface expression pattern of the different mesenchymal stem cells analyzed, fibroblasts and pluripotent stem cells

		Fibroblasts	PSC	PD-MSC _PL	PD-MSC _FBS	UC-MSC
Mesenchymal stem cell markers	CD90	+++	+++	+++	+++	+++
	CD73	++	–	+++	+++	+++
	CD105	++	–	+++	+++	+++
	CD166	+++	–	+++	+++	+++
	CD172alpha	+	–	+	+	++
	CD271	–	+	+	+	+
Pluripotent stem cell markers	Tra-1-60	–	+++	–	–	–
	CD133	–	+++	–	–	–
	CD309	–	++	–	–	–
Integrins	CD29	+++	+++	+++	+++	+++
	CD49a	+++	–	+++	+	++
	CD49d	+++	–	+++	+++	+++
	CD49e	+++	+++	+++	+++	+++
	CD49f	+++	+++	+++	+++	+++
	CD51/61	+++	–	+++	+++	+++

Markers are grouped according to phenotype. No major difference was found between fibroblasts, PD-MSC_PL, PD-MSC_FBS and UC-MSC. Some markers, however, are useful to distinguish between PSC and mesenchymal cells. –, no expression; +, mild expression; ++, medium expression; +++, strong expression. PD-MSC_FBS, pluripotent-derived mesenchymal stem cells supplemented with fetal bovine serum; PD-MSC_PL, pluripotent-derived mesenchymal stem cells supplemented with platelet lysate; PSC, pluripotent stem cells; UC-MSC, umbilical cord mesenchymal stem cells.

ISSN: 1757-6512